



Onyx Dkt No. ONYX1047.DIV
USSN: 10/669,768
PATENT

Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the following date:

3 April 2006

Date

Gary R Fabian

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	
In Re Application of: Shen, Y., et al.	Confirmation No. 8135
Serial No.: 10/669,768	Art Unit: 1633
Filing Date: 24 September 2003	Examiner: M. Marvich
Title: ADENOVIRUS E1B-55K SINGLE AMINO ACID MUTANTS AND METHODS OF USE	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing are an Information Disclosure Statement and a modified Form PTO-1449. Copies of the newly cited U.S. Patents (6,635,244 and 6,080,578) are not enclosed pursuant the "Changes to Support Implementation of the United States Patent and Trademark Office 21st Century Strategic Plan," Federal Register, Vol. 69, No. 182.

All other cited references are already of record in parent application USSN:09/918,696, now U.S. Patent No. 6,635,244. Accordingly, additional copies of the references already of record in the parent application are not being submitted.

The Examiner is respectfully requested to make this information of official record in the application.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

It is believed that no fee is due as this Information Disclosure Statement is being submitted before the first action on the merits.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 15-0615. However, this is not authorization to pay the Issue Fee.

Respectfully submitted,

Dated: 3 Apr 2006

By : Gary R. Fabian
Gary R. Fabian
Agent for Applicants
Registration No. 33,875

ONYX Pharmaceuticals, Inc.
2100 Powell Street
Emeryville, CA 94608
Phone: (510) 597-6502
Facsimile: (510) 597-6610

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Onyx Dkt No. ONYX 1047.DIV

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Sheet 1 of 1

Application of: Shen, Y., et al.
Serial No.: 10/669,768
Filed: 24 September 2003
Title: ADENOVIRUS E1B-55K SINGLE AMINO ACID MUTANTS AND METHODS OF USE

Confirmation No.: 8135
Art Unit: 1633
Examiner: M. Marvich

U.S. PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
	AA-01	5,677,178	Oct. 1997	McCormick			
	AA-02	6,635,244	Oct. 2003	Shen, et al.			
	AA-03	6,080,578	June 2000	Bischoff, et al.			

FOREIGN PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Translation YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Exam. Init.	Ref. Desig.	Description
	AC-01	Cheng, et al., 1990, "Domains Required for in Vitro Associated between the Cellular p53 and the Adenovirus 2 E1B 55K Proteins.", Virology, 179:806-814.
	AC-02	Harda, et al., 1999, "p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication." Journal of Virology, 73(7):5333-5344.
	AC-03	Shen, et al., 2001, "Analyses of Single-Amino Acid Substitution Mutants of Adenovirus Type 5 E1B-55K Protein." Journal of Virology, 75(9):4297-4307.
	AC-04	Yew, et al., 1990, Dissection of Functional Domains in the Adenovirus 2 Early 1B 55K Polypeptide by Suppressor-Linker Insertional Mutagenesis., Virology, 179:795-805.

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.